<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: following cautionary", fill: "#7d7"},
{source: "2: following cautionary", target: "2: risks uncertainties", fill: "#7d7"},
{source: "2: risks uncertainties", target: "2: possibly inaccurate assumptions", fill: "#7d7"},
{source: "2: following cautionary", target: "7: Consequently ", fill: "#1e90ff"},
{source: "7: Consequently ", target: "7: potential risks", fill: "#1e90ff"},
{source: "7: potential risks", target: "7: uncertainties", fill: "#1e90ff"},
{source: "7: Consequently ", target: "9: manufacturers", fill: "#004953"},
{source: "9: manufacturers", target: "9: on successfully", fill: "#004953"},
{source: "9: on successfully", target: "9: steady flow", fill: "#004953"},
{source: "9: steady flow", target: "9: generic products", fill: "#004953"},
{source: "9: manufacturers", target: "12: Therefore ", fill: "#ee82ee"},
{source: "12: Therefore ", target: "12: currently marketed products", fill: "#ee82ee"},
{source: "12: currently marketed products", target: "12: newly launched", fill: "#ee82ee"},
{source: "12: newly launched", target: "12: generic product", fill: "#ee82ee"},
{source: "12: generic product", target: "12: additional generic competition from one", fill: "#ee82ee"},
{source: "12: additional generic competition from one", target: "12: competing products", fill: "#ee82ee"},
{source: "12: competing products", target: "12: affected generic", fill: "#ee82ee"},
{source: "12: affected generic", target: "12: dramatically", fill: "#ee82ee"},
{source: "12: Therefore ", target: "14: largest single", fill: "#b31b1b"},
{source: "14: largest single", target: "14: generic products", fill: "#b31b1b"},
{source: "14: generic products", target: "14: oral contraceptives", fill: "#b31b1b"},
{source: "14: oral contraceptives", target: "14: which accounted", fill: "#b31b1b"},
{source: "14: largest single", target: "15: recorded revenues", fill: "#c50"},
{source: "15: recorded revenues", target: "15: Desmopressin ", fill: "#c50"},
{source: "15: Desmopressin ", target: "15: of a Allegra ", fill: "#c50"},
{source: "15: recorded revenues", target: "20: Competition ", fill: "#7df9ff"},
{source: "20: Competition ", target: "20: manufacturer", fill: "#7df9ff"},
{source: "20: manufacturer", target: "20: proprietary products", fill: "#7df9ff"},
{source: "20: proprietary products", target: "20: regulatory", fill: "#7df9ff"},
{source: "20: regulatory", target: "20: exclusivity", fill: "#7df9ff"},
{source: "20: exclusivity", target: "20: generic version", fill: "#7df9ff"},
{source: "20: generic version", target: "20: adversely affect", fill: "#7df9ff"},
{source: "20: Competition ", target: "22: competitor", fill: "#3b3c36"},
{source: "22: competitor", target: "22: generic version", fill: "#3b3c36"},
{source: "22: generic version", target: "22: SEASONALE ", fill: "#3b3c36"},
{source: "22: SEASONALE ", target: "22: regulatory", fill: "#3b3c36"},
{source: "22: regulatory", target: "22: exclusivity", fill: "#3b3c36"},
{source: "22: exclusivity", target: "22: September ", fill: "#3b3c36"},
{source: "22: competitor", target: "24: Resolving Paragraph IV ", fill: "#e4717a"},
{source: "24: Resolving Paragraph IV ", target: "24: patent challenges", fill: "#e4717a"},
{source: "24: patent challenges", target: "24: historically", fill: "#e4717a"},
{source: "24: historically", target: "24: significant", fill: "#e4717a"},
{source: "24: significant", target: "24: contributions from products", fill: "#e4717a"},
{source: "24: contributions from products", target: "24: patent challenge activities", fill: "#e4717a"},
{source: "24: Resolving Paragraph IV ", target: "25: in the Contents ", fill: "#0f4d92"},
{source: "25: in the Contents ", target: "25: permit us", fill: "#0f4d92"},
{source: "25: permit us", target: "25: generic versions", fill: "#0f4d92"},
{source: "25: generic versions", target: "25: through settlements", fill: "#0f4d92"},
{source: "25: through settlements", target: "25: competitors", fill: "#0f4d92"},
{source: "25: competitors", target: "25: pursue patent challenges", fill: "#0f4d92"},
{source: "25: pursue patent challenges", target: "25: difficult", fill: "#0f4d92"},
{source: "25: difficult", target: "25: Paragraph IV ", fill: "#0f4d92"},
{source: "25: Paragraph IV ", target: "25: certification on", fill: "#0f4d92"},
{source: "25: certification on", target: "25: patent protected product", fill: "#0f4d92"},
{source: "25: patent protected product", target: "25: branded companys decision", fill: "#0f4d92"},
{source: "25: branded companys decision", target: "25: authorized generic version", fill: "#0f4d92"},
{source: "25: authorized generic version", target: "25: product will reduce", fill: "#0f4d92"},
{source: "25: product will reduce", target: "25: authorized generic", fill: "#0f4d92"},
{source: "25: authorized generic", target: "25: brought by third parties", fill: "#0f4d92"},
{source: "25: brought by third parties", target: "25: Attorneys General ", fill: "#0f4d92"},
{source: "25: Attorneys General ", target: "25: settlement agreements could affect", fill: "#0f4d92"},
{source: "25: settlement agreements could affect", target: "25: patent challenges with", fill: "#0f4d92"},
{source: "25: patent challenges with", target: "25: pharmaceutical companies", fill: "#0f4d92"},
{source: "25: pharmaceutical companies", target: "25: use legislative", fill: "#0f4d92"},
{source: "25: use legislative", target: "25: regulatory", fill: "#0f4d92"},
{source: "25: regulatory", target: "25: generic products", fill: "#0f4d92"},
{source: "25: in the Contents ", target: "27: pharmaceutical industry as", fill: "#fddde6"},
{source: "27: pharmaceutical industry as", target: "27: at risk launch", fill: "#fddde6"},
{source: "27: pharmaceutical industry as", target: "31: managed healthcare", fill: "#987654"},
{source: "31: managed healthcare", target: "31: organizations", fill: "#987654"},
{source: "31: organizations", target: "31: HMOs and MCOs ", fill: "#987654"},
{source: "31: HMOs and MCOs ", target: "31: legislative", fill: "#987654"},
{source: "31: legislative", target: "31: government", fill: "#987654"},
{source: "31: government", target: "31: significantly", fill: "#987654"},
{source: "31: significantly", target: "31: pharmaceutical", fill: "#987654"},
{source: "31: pharmaceutical", target: "31: product demand", fill: "#987654"},
{source: "31: managed healthcare", target: "38: inability", fill: "#e48400"},
{source: "38: inability", target: "38: successfully formulate", fill: "#e48400"},
{source: "38: successfully formulate", target: "38: pass bioequivalence studies", fill: "#e48400"},
{source: "38: pass bioequivalence studies", target: "38: adversely affect", fill: "#e48400"},
{source: "38: adversely affect", target: "38: generic products", fill: "#e48400"},
{source: "38: inability", target: "START_HERE", fill: "#e48400"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Diversified Financial Services</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Uncertainty">Uncertainty</a></td>
      <td>Uncertainty refers to epistemic situations involving imperfect or unknown information. It applies to predictions of future events, to physical measurements that are already made, or to the unknown.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Propagation_of_uncertainty">Propagation of uncertainty</a></td>
      <td>In statistics, propagation of uncertainty (or propagation of error) is the effect of variables' uncertainties (or errors, more specifically random errors) on the uncertainty of a function based on them. When the variables are the values of experimental measurements they have uncertainties due to measurement limitations (e.g., instrument precision) which propagate due to the combination of variables in the function.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fear,_uncertainty,_and_doubt">Fear, uncertainty, and doubt</a></td>
      <td>Fear, uncertainty, and doubt (often shortened to FUD) is a propaganda tactic used in sales, marketing, public relations, politics, polling and cults. FUD is generally a strategy to influence perception by disseminating negative and dubious or false information and a manifestation of the appeal to fear.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_computer_hardware_manufacturers">List of computer hardware manufacturers</a></td>
      <td>Current notable computer hardware manufacturers:\n\n\n== Cases ==\nList of computer case manufacturers:\n\n\n=== Rack-mount computer cases ===\n\n\n== Laptop computer cases ==\nClevo\nMSI\n\n\n== Motherboards ==\nTop motherboard manufacturers:\n\nList of motherboard manufacturers:\n\nDefunct:\n\n\n== Chipsets for motherboards ==\n\n\n== Central processing units (CPUs) ==\nNote: most of these companies only make designs, and do not manufacture their own designs. \nTop x86 CPU manufacturers:\n\nList of CPU manufacturers (most of the companies sell ARM-based CPUs, assumed if nothing else stated):\n\nAcquired or defunct:\n\n\n== Hard disk drives (HDDs) ==\n\n\n=== Internal ===\nList of current hard disk drive manufacturers:\n\nSeagate Technology\nToshiba\nWestern Digital\n\n\n=== External ===\nNote: the HDDs internal to these devices are manufactured only by the internal HDD manufacturers listed above.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_price">List price</a></td>
      <td>The list price, also known as the manufacturer's suggested retail price (MSRP), or the recommended retail price (RRP), or the suggested retail price (SRP) of a product is the price at which its manufacturer notionally recommends that a retailer sell the product.\nSuggested pricing methods may conflict with competition theory, as they allow prices to be set higher than would be established by supply and demand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Successful_(song)">Successful (song)</a></td>
      <td>"Successful" is a song by Canadian rapper Drake and R&amp;B singer Trey Songz . The song features guest appearances from Drake's mentor and labelmate Lil Wayne.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Successful_Pyrate">The Successful Pyrate</a></td>
      <td>The Successful Pyrate is a play by Charles Johnson, first performed 1712, published 1713, dealing with the life of the pirate Henry Avery. It opened at the Theatre Royal, Drury Lane on 7 November 1712 and ran for five evenings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/A_Successful_Failure">A Successful Failure</a></td>
      <td>A Successful Failure is a 1934 American film directed by Arthur Lubin. It was Lubin's first film as director.There is no connection between the fictional radio personality "Uncle Dudley" in this film, and the 1935 comedy film Your Uncle Dudley, with Edward Everett Horton.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Generic_brand">Generic brand</a></td>
      <td>Generic brands of consumer products (often supermarket goods) are distinguished by the absence of a brand name, instead identified solely by product characteristics and identified by plain, usually black-and-white packaging. Generally they imitate more expensive branded products, competing on price.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Generic_trademark">Generic trademark</a></td>
      <td>A generic trademark, also known as a genericized trademark or proprietary eponym, is a trademark or brand name that, because of its popularity or significance, has become the generic term for, or synonymous with, a general class of products or services, usually against the intentions of the trademark's owner.\nA trademark is said to become genericized—or, informally, to have suffered genericide—when it begins as a distinctive product identifier but changes in meaning to become generic.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Apotex">Apotex</a></td>
      <td>Apotex Inc. is a Canadian pharmaceutical corporation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Combined_oral_contraceptive_pill">Combined oral contraceptive pill</a></td>
      <td>The combined oral contraceptive pill (COCP), often referred to as the birth control pill or colloquially as "the pill", is a type of birth control that is designed to be taken orally by women. It includes a combination of an estrogen (usually ethinylestradiol) and a progestogen (specifically a progestin).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Extended_cycle_combined_hormonal_contraceptive">Extended cycle combined hormonal contraceptive</a></td>
      <td>Extended or continuous cycle combined oral contraceptive pills are a packaging of combined oral contraceptive pills (COCPs) that reduce or eliminate the withdrawal bleeding that would occur once every 28 days in traditionally packaged COCPs.  It works by reducing the frequency of the pill-free or placebo days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Desmopressin">Desmopressin</a></td>
      <td>Desmopressin, sold under the trade name DDAVP among others, is a medication used to treat diabetes insipidus, bedwetting, hemophilia A, von Willebrand disease, and high blood urea levels. In hemophilia A and von Willebrand disease, it should only be used for mild to moderate cases.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fluid_deprivation_test">Fluid deprivation test</a></td>
      <td>A fluid or water deprivation test is a medical test which can be used to determine whether the patient has diabetes insipidus as opposed to other causes of polydipsia (a condition of excessive thirst that causes an excessive intake of water). The patient is required, for a prolonged period, to forgo intake of water completely, to determine the cause of the thirst.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Von_Willebrand_disease">Von Willebrand disease</a></td>
      <td>Von Willebrand disease (VWD) is the most common hereditary blood-clotting disorder in humans. An acquired form can sometimes result from other medical conditions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Enuresis">Enuresis</a></td>
      <td>Enuresis is a repeated inability to control urination. Use of the term is usually limited to describing people old enough to be expected to exercise such control.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Haemophilia_A">Haemophilia A</a></td>
      <td>Haemophilia, or hemophilia (from Ancient Greek  αἷμα (haîma) 'blood', and  φιλία (philía) 'love of'), is a mostly inherited genetic disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding. This results in people bleeding for a longer time after an injury, easy bruising, and an increased risk of bleeding inside joints or the brain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_agency">Regulatory agency</a></td>
      <td>A regulatory agency (regulatory body, regulator) or independent agency (independent regulatory agency) is a government authority that is responsible for exercising autonomous dominion over some area of human activity in a licensing and regulating capacity.\nThese are customarily set up to strengthen safety and standards, and/or to protect consumers in markets where there is a lack of effective competition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sign">Regulatory sign</a></td>
      <td>A regulatory sign is used to indicate or reinforce traffic laws, regulations or requirements which apply either at all times or at specified times or places upon a street or highway, the disregard of which may constitute a violation, or a sign in general that regulates public behavior in places open to the public.  The FHWA defines regulatory sign as "a sign that gives notice to road users of traffic laws or regulations".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cis-regulatory_element">Cis-regulatory element</a></td>
      <td>Cis-regulatory elements (CREs) or Cis-regulatory modules (CRMs) are regions of non-coding DNA which regulate the transcription of neighboring genes. CREs are vital components of genetic regulatory networks, which in turn control morphogenesis, the development of anatomy, and other aspects of embryonic development, studied in evolutionary developmental biology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sport_of_athletics">Sport of athletics</a></td>
      <td>Athletics is a group of sporting events that involves competitive running, jumping, throwing, and walking. The most common types of athletics competitions are track and field, road running, cross country running, and racewalking.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Round-robin_tournament">Round-robin tournament</a></td>
      <td>A round-robin tournament (or all-play-all tournament) is a competition in which each contestant meets every other participant, usually in turn. A round-robin contrasts with an elimination tournament, in which participants are eliminated after a certain number of losses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Patent">Patent</a></td>
      <td>A patient is any recipient of health care services that are performed by healthcare professionals. The patient is most often ill or injured and in need of treatment by a physician, nurse, optometrist, dentist, veterinarian, or other health care provider.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Patent_troll">Patent troll</a></td>
      <td>In international law and business, patent trolling or patent hoarding is a categorical or pejorative term applied to a person or company that attempts to enforce patent rights against accused infringers far beyond the patent's actual value or contribution to the prior art, often through hardball legal tactics (frivolous litigation, vexatious litigation, strategic lawsuits against public participation (SLAPP), chilling effects, and the like). Patent trolls often do not manufacture products or supply services based upon the patents in question.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Others">Significant Others</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Mother">Significant Mother</a></td>
      <td>Significant Mother is an American television sitcom created by Erin Cardillo and Richard Keith. Starring Josh Zuckerman, Nathaniel Buzolic and Krista Allen, it premiered on The CW network on August 3 and ended its run on October 5, 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gross_domestic_product">Gross domestic product</a></td>
      <td>Gross domestic product (GDP) is a monetary measure of the market value of all the final goods and services produced in a specific time period by countries. GDP (nominal) per capita does not, however, reflect differences in the cost of living and the inflation rates of the countries; therefore, using a basis of GDP per capita at purchasing power parity (PPP) may be more useful when comparing living standards between nations, while nominal GDP is more useful comparing national economies on the international market.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_industry">Pharmaceutical industry</a></td>
      <td>The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate symptoms.  Pharmaceutical companies may deal in generic or brand medications and medical devices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sun_Pharma">Sun Pharma</a></td>
      <td>Sun Pharmaceutical Industries Limited (d/b/a Sun Pharma) is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs)  in more than 100 countries across the globe. It is largest pharma company in India and the fourth largest specialty generic pharmaceutical company in the world, with a total revenue of over US$4.5 billion as of June 2021.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmacy">Pharmacy</a></td>
      <td>Pharmacy is the clinical health science that links medical science with chemistry and it is charged with the discovery, production, disposal, safe and effective use, and control of medications and drugs. The practice of pharmacy requires excellent knowledge of drugs, their mechanism of action, side effects, interactions, mobility and toxicity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Anosmia">Anosmia</a></td>
      <td>Anosmia, also known as smell blindness, is the loss of the ability to detect one or more smells. Anosmia may be temporary or permanent.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aphantasia">Aphantasia</a></td>
      <td>Aphantasia is the inability to voluntarily create mental images in one's mind.The phenomenon was first described by Francis Galton in 1880 but has since remained relatively unstudied. Interest in the phenomenon renewed after the publication of a study in 2015 conducted by a team led by Professor Adam Zeman of the University of Exeter.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>BARR PHARMACEUTICALS INC      ITEM 1A RISK FACTORS          The statements in this section describe the <font color="blue">major risks</font> to our business     and should be considered <font color="blue">carefully</font></td>
    </tr>
    <tr>
      <td>We provide the <font color="blue">following cautionary</font>     discussion of risks, <font color="blue">uncertainties</font> and <font color="blue">possibly inaccurate assumptions</font>     relevant to our business</td>
    </tr>
    <tr>
      <td>These are factors that, individually or in the     aggregate, we think could cause our actual results to <font color="blue">differ materially from</font>     expected  and historical results</td>
    </tr>
    <tr>
      <td>Our business, <font color="blue">financial condition</font> or     results of <font color="blue">operations could</font> be <font color="blue">materially <font color="blue">adversely</font> affected by</font> any of these     risks</td>
    </tr>
    <tr>
      <td>We  note  these factors for <font color="blue">investors as permitted by</font> the Private     Securities Litigation Reform Act of 1995</td>
    </tr>
    <tr>
      <td>You should understand that it is     not possible to predict or identify all <font color="blue">such factors</font></td>
    </tr>
    <tr>
      <td>Consequently, you     should  not  consider the following to be a complete discussion of all     <font color="blue">potential risks</font> or <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>See “Item 7, “Management’s Discussion and     Analysis of Financial Condition and Results of Operations —Forward-Looking     Statements</td>
    </tr>
    <tr>
      <td>”                                         29       _________________________________________________________________    [60]Table of <font color="blue">Contents       </font>Competition from other <font color="blue"><font color="blue">manufacturer</font>s</font> of generic drugs affecting our generic     products          The success of our generic business is based in part <font color="blue">on <font color="blue">successfully</font></font>     developing and bringing to market a <font color="blue">steady flow</font> of <font color="blue"><font color="blue">generic product</font>s</font></td>
    </tr>
    <tr>
      <td>We     attempt to select our <font color="blue"><font color="blue">generic product</font>s</font> based on the prospects for limited     <font color="blue">competition from competing generic companies</font></td>
    </tr>
    <tr>
      <td>We do so because we believe     that the more <font color="blue">generic <font color="blue">competitor</font>s</font> that market the <font color="blue">same <font color="blue">generic product</font></font>, the     lower  the  revenue  and <font color="blue">profitability</font> we will record for our product</td>
    </tr>
    <tr>
      <td>Therefore, if any of our <font color="blue">currently marketed products</font> or any <font color="blue">newly launched</font>     <font color="blue">generic product</font> are subject to <font color="blue">additional generic competition from one</font> or     more <font color="blue">competing products</font>, our price and market share for the <font color="blue">affected generic</font>     product  could  be  <font color="blue">dramatically</font>  reduced</td>
    </tr>
    <tr>
      <td>As a consequence, unless we     <font color="blue">successfully</font> replace <font color="blue"><font color="blue">generic product</font>s</font> that are declining in <font color="blue">profitability</font>     with new <font color="blue"><font color="blue">generic product</font>s</font> with higher <font color="blue">profitability</font>, our business could be     <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Our <font color="blue">largest single</font> category of <font color="blue"><font color="blue">generic product</font>s</font> is <font color="blue">oral contraceptives</font>,     <font color="blue">which accounted</font> for approximately dlra400 million in revenues in fiscal 2006</td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">recorded revenues</font> of dlra90 million or more from each of two     other <font color="blue"><font color="blue">generic product</font>s</font>, Desmopressin, and royalties from the sale of a     generic  version  of  Allegra  by  Teva  Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Two generic     <font color="blue"><font color="blue">manufacturer</font>s</font>  have  already  launched  a competing <font color="blue">generic version</font> of     Desmopressin,  and there are two competing generic Allegra products in     addition to Teva’s</td>
    </tr>
    <tr>
      <td>We anticipate <font color="blue">added competition</font> to <font color="blue">Desmopressin </font>and     Allegra over time</td>
    </tr>
    <tr>
      <td>In addition, we anticipate <font color="blue">increasing competition</font> to our     generic <font color="blue">oral contraceptives</font> over time</td>
    </tr>
    <tr>
      <td>Unless we can replace the anticipated     losses of revenues from these <font color="blue">products with revenues from <font color="blue">new products</font></font>, our     revenues and <font color="blue">profitability</font> will suffer</td>
    </tr>
    <tr>
      <td><font color="blue">Competition  </font>from  other  <font color="blue"><font color="blue">manufacturer</font>s</font> of generic drugs affecting our     <font color="blue"><font color="blue">proprietary</font> products</font>          Upon  the  expiration  or loss of patent protection or <font color="blue">regulatory</font>     <font color="blue">exclusivity</font> periods for one of our branded products, or upon the “at-risk”     launch by a generic <font color="blue">manufacturer</font> of a <font color="blue">generic version</font> of one of our branded     products, we can lose the major portion of sales of that product in a very     short  period,  which  can <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>For example,     SEASONALE, our largest selling <font color="blue">proprietary</font> product, generated dlra100 million     in revenues during fiscal 2006</td>
    </tr>
    <tr>
      <td>In May 2006 a <font color="blue">competitor</font> received tentative     FDA approval for a <font color="blue">generic version</font> of <font color="blue">SEASONALE </font>and may be eligible for     final approval following the expiration of our <font color="blue">regulatory</font> <font color="blue">exclusivity</font> on     <font color="blue">September </font>5, 2006</td>
    </tr>
    <tr>
      <td>If the <font color="blue">competitor</font> launches its product, our revenues and     gross profit <font color="blue">contributions</font> from <font color="blue">SEASONALE </font><font color="blue">will decline <font color="blue">significant</font>ly</font></td>
    </tr>
    <tr>
      <td><font color="blue">Resolving Paragraph IV </font><font color="blue">patent challenges</font>          Our  operating  results  have  <font color="blue">historically</font>  included <font color="blue">significant</font>     <font color="blue">contributions</font> from products that arise from the success we have had from our     <font color="blue">patent challenge activities</font></td>
    </tr>
    <tr>
      <td>However, the success we have had in the past     from                                         30       _________________________________________________________________    [61]Table of <font color="blue">Contents       </font>challenging branded companies’ patents, whether through court decisions that     <font color="blue">permit us</font> to launch our <font color="blue">generic version</font>s of product or <font color="blue">through settlements</font>,     may not be repeated in the future due to the following:       •   an increase in the number of <font color="blue">competitor</font>s who pursue <font color="blue">patent challenges</font>     could make it more <font color="blue">difficult</font> for us to be first to file a <font color="blue">Paragraph IV     </font><font color="blue">certification on</font> a <font color="blue">patent protected product</font>;         •   a branded company’s decision to launch an “authorized” <font color="blue">generic version</font>     of the <font color="blue">product will reduce</font> our market share and lower the revenues and gross     profits we could have otherwise earned if an “authorized” generic were not     launched;         •   claims <font color="blue">brought by <font color="blue">third parties</font></font>, including the FTC, various states’     <font color="blue">Attorneys General </font>and other third-party payers challenging the legality of     our <font color="blue">settlement agreements could affect</font> the way in which we resolve our     <font color="blue">patent challenges</font> with the brand <font color="blue"><font color="blue">pharmaceutical</font> companies</font>; and         •   the efforts of brand companies to <font color="blue">use <font color="blue">legislative</font></font> and <font color="blue">regulatory</font>     tactics to delay the launch of <font color="blue"><font color="blue">generic product</font>s</font></td>
    </tr>
    <tr>
      <td>Impact of “At Risk” launches          There are situations where we have used our business and <font color="blue">legal judgment</font>     and decided to market and <font color="blue">sell products</font>, subject to claims of alleged patent     <font color="blue">infringement</font>, prior to <font color="blue">final resolution by</font> the courts, based upon our belief     that <font color="blue">such patents</font> are invalid, unenforceable, or would not be infringed</td>
    </tr>
    <tr>
      <td>This is referred to in the <font color="blue"><font color="blue">pharmaceutical</font> industry as</font> an “at risk” launch</td>
    </tr>
    <tr>
      <td>The <font color="blue">risk involved</font> in doing so can be substantial because if a <font color="blue">patent holder</font>     <font color="blue">ultimately prevails</font>, the <font color="blue">remedies available</font> to such holder include, among     other things, damages measured by the profits lost by the <font color="blue">holder which</font> are     often <font color="blue">significant</font>ly higher than the profits we make <font color="blue">from selling</font> the generic     version of the product</td>
    </tr>
    <tr>
      <td>Should we elect to proceed in this manner we could     face substantial damages if the <font color="blue">final court decision</font> is adverse to us</td>
    </tr>
    <tr>
      <td>In     the case where a <font color="blue">patent holder</font> was able to prove that our <font color="blue">infringement</font> was     “willful”,  the <font color="blue">definition</font> of which is subjective, such damages may be     trebled</td>
    </tr>
    <tr>
      <td>Government Regulation and Managed Care Trends          The  trend  toward  <font color="blue">managed healthcare</font> in the US, the growth of     <font color="blue">organizations</font> such as <font color="blue">HMOs and MCOs </font>and <font color="blue">legislative</font> proposals to reform     healthcare and <font color="blue">government</font> insurance programs could <font color="blue">significant</font>ly influence     the purchase of <font color="blue">pharmaceutical</font> products, resulting in lower prices and a     reduction in <font color="blue">product demand</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">cost containment measures</font> and healthcare     <font color="blue">reform could affect</font> our ability to sell our products and may have a material     adverse effect on us</td>
    </tr>
    <tr>
      <td>Additionally, <font color="blue">reimbursements</font> to <font color="blue">patients may</font> not be     maintained  and  third-party  payers,  which place <font color="blue">limits on levels</font> of     reimbursement, may reduce the demand for, or <font color="blue">negatively affect</font> the price of,     those products and could <font color="blue">significant</font>ly harm our business</td>
    </tr>
    <tr>
      <td>We may also be     subject to lawsuits relating to <font color="blue">reimbursement programs</font> that could be costly     to defend, divert management’s attention and could have a material adverse     effect on our business</td>
    </tr>
    <tr>
      <td>Development and Regulatory Approval          Risks and <font color="blue">uncertainties</font> <font color="blue">particularly</font> apply to whether or when our     products will be approved</td>
    </tr>
    <tr>
      <td>The outcome of the lengthy and <font color="blue">complex process</font> of     developing <font color="blue">new products</font> is <font color="blue">inherently uncertain</font></td>
    </tr>
    <tr>
      <td>For our generic business, much of our <font color="blue">product development efforts</font> are     focused  on developing products that are <font color="blue">difficult</font> to formulate and/or     products that require <font color="blue">specialized <font color="blue">manufacturing</font> technology</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">inability</font> to     <font color="blue">successfully</font> formulate and <font color="blue">pass bioequivalence studies</font> can <font color="blue">adversely</font> affect     the timing of when we receive approval for our <font color="blue"><font color="blue">generic product</font>s</font></td>
    </tr>
    <tr>
      <td>For our <font color="blue">proprietary</font> business, <font color="blue">regulatory</font> delays, the <font color="blue">inability</font> to     <font color="blue">successfully</font> complete <font color="blue">clinical trials</font> or claims and <font color="blue">concerns about safety</font>     and efficacy are a few of the factors that could <font color="blue">adversely</font> affect the timing     of new                                         31       _________________________________________________________________    [62]Table of <font color="blue">Contents       </font><font color="blue">proprietary</font>  product  launches</td>
    </tr>
    <tr>
      <td>In  addition  decisions by <font color="blue">regulatory</font>     <font color="blue">authorities</font> regarding labeling and other matters could <font color="blue">adversely</font> affect the     <font color="blue">availability</font> or <font color="blue">commercial potential</font> of our products</td>
    </tr>
    <tr>
      <td>There  can  be <font color="blue">no assurance as</font> to whether or when we will receive     <font color="blue">regulatory</font> approval for <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>Product Manufacturing and Marketing          Difficulties  or  delays  in  product <font color="blue">manufacturing</font> or marketing,     including, but not limited to, the <font color="blue">inability</font> to <font color="blue">increase production capacity</font>     <font color="blue">commensurate with demand</font>, or the failure to <font color="blue">predict market demand</font> for, or to     <font color="blue">gain market acceptance</font> of <font color="blue">approved products</font>, including our <font color="blue">recent launches</font>     of SEASONIQUE and ENJUVIA, <font color="blue">could affect future</font> results</td>
    </tr>
    <tr>
      <td><font color="blue">Dependence </font><font color="blue">on <font color="blue">third parties</font></font>          We rely <font color="blue">on <font color="blue">third parties</font></font> to supply us with raw materials, inactive     <font color="blue">ingredients</font> and other <font color="blue">components</font> for our <font color="blue">manufactured products</font> and for     certain of our finished goods</td>
    </tr>
    <tr>
      <td>In many <font color="blue">instances there</font> is only a single     supplier</td>
    </tr>
    <tr>
      <td>In addition, we rely on third-party <font color="blue">distributors</font> and alliance     partners  to  provide  services  for  our  business, including product     development, <font color="blue">manufacturing</font>, warehousing, <font color="blue">distribution</font>, customer service     support,  medical  affairs services, clinical studies, sales and other     technical and <font color="blue">financial services</font> for certain of our products</td>
    </tr>
    <tr>
      <td>Nearly all     third-party suppliers and <font color="blue">contractors</font> are subject to FDA, and in some cases     DEA,  <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Our business on some products are <font color="blue">dependent on</font> the     <font color="blue">regulatory</font> compliance of these <font color="blue">third parties</font>, and on the strength, validity     and terms of our <font color="blue">various contracts with</font> these third-party <font color="blue"><font color="blue">manufacturer</font>s</font>,     <font color="blue">distributors</font> and <font color="blue">collaboration partners</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">interruption</font> or <font color="blue">failure by</font>     these suppliers, <font color="blue">distributors</font> and <font color="blue">collaboration partners</font> to meet their     <font color="blue">obligations pursuant</font> to <font color="blue">various agreements</font> or <font color="blue">obligations with us could</font> have     a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>In  addition, our revenues include amounts we <font color="blue">earn based on sales</font>     generated and <font color="blue">recorded by</font> <font color="blue">Teva Pharmaceuticals </font>for generic Allegra, and Kos     Pharmaceuticals for Niaspan and Advicor</td>
    </tr>
    <tr>
      <td>Any factors that <font color="blue">negatively impact</font>     the sales of these products could <font color="blue">adversely</font> impact our revenues and profits</td>
    </tr>
    <tr>
      <td>Customer <font color="blue">consolidation</font>          Our <font color="blue">principal customers</font> are wholesale drug <font color="blue">distributors</font> and major     <font color="blue">retail drug store chains</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">customers comprise</font> a <font color="blue">significant</font> part of the     <font color="blue">distribution</font>  network  for  <font color="blue">pharmaceutical</font>  products  in the <font color="blue">US This     </font><font color="blue">distribution</font> network is continuing to undergo <font color="blue">significant</font> <font color="blue">consolidation</font>     marked by mergers and acquisitions among wholesale <font color="blue">distributors</font> and the     growth of large <font color="blue">retail drug store chains</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">consolidation</font> may result in     these  groups  <font color="blue">gaining additional purchasing leverage</font> and <font color="blue">consequently</font>     increasing the <font color="blue">product pricing pressures facing</font> our business</td>
    </tr>
    <tr>
      <td>Additionally,     the  emergence  of large buying groups <font color="blue">representing</font> <font color="blue">independent</font> retail     pharmacies and the prevalence and influence of managed care <font color="blue">organizations</font>     and similar <font color="blue">institutions potentially enable</font> those groups to attempt to     <font color="blue">extract price discounts on</font> our products</td>
    </tr>
    <tr>
      <td>Our net sales and <font color="blue">quarterly growth</font>     <font color="blue">comparisons may</font> be <font color="blue">affected by fluctuations</font> in the <font color="blue">buying patterns</font> of major     <font color="blue">distributors</font>, retail chains and other <font color="blue">trade buyers</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">fluctuations may</font>     result from seasonality, pricing, wholesaler buying decisions or other     factors</td>
    </tr>
    <tr>
      <td>Cost and Expense Control/Unusual Events          Growth in costs and expenses, changes in product mix and the impact of     acquisitions, divestitures, restructurings, product withdrawals and other     unusual  events  that  could result <font color="blue">from evolving</font> business strategies,     <font color="blue">evaluation</font> of <font color="blue">asset realization</font> and <font color="blue">organizational restructuring could</font>     create <font color="blue">volatility</font> in our results</td>
    </tr>
    <tr>
      <td>Such risks and <font color="blue">uncertainties</font> include, in     particular, the potentially <font color="blue">significant</font> charges to our operating results for     items like in-process research and <font color="blue">development charges</font> and <font color="blue">transaction</font>     costs</td>
    </tr>
    <tr>
      <td><font color="blue">Legal Proceedings</font></td>
    </tr>
  </tbody>
</table>